SEP 01, 2016 4:58 AM PDT

Drug Clears Toxic Protein Clusters in Alzheimer's Brain

WRITTEN BY: Xuan Pham
The beloved actor Gene Wilder died earlier this week from complications of Alzheimer’s disease. He was one of the tens of thousands of people who succumb to the disease, according to the Centers for Disease Control and Prevention.
 
But there’s some hope peeking through the grim statistics of this disease. Scientists recently announced highly promising results of a drug that purportedly can erase the toxic protein clumps in the Alzheimer brain.
 
Promising results for experimental Alzheimer drug | Image: pexels.com
The drug, known as aducanumab, targets the amyloid beta plaques in the brains of animal models, and now also in human clinical trials. As this drug progresses to Phase 3 to test efficacy in a larger group of patients, researchers are hopeful it will become the first drug to actually reverse Alzheimer pathology.
 
Amyloid plaque clumps (yellow) in the brainAlzheimer’s disease is pathologically defined with the presence of amyloid beta protein clumps in the brain. These are toxic to neurons and interfere with memory, cognition, and other normal functions of the brain. The CDC estimated 85,000 people died from Alzheimer’s disease in 2015; however, this number is believed to be an underestimate, as many deaths may not be correctly attributed to Alzheimer’s.
 
Aducanumab is an immune compound that appears to stimulate the body to remove the toxic amyloid clumps. In the latest study, scientists split 165 patients with mild Alzheimer’s disease into two groups: those who received aducanumab and those who received a placebo. This was done for 1 year, with the intent on demonstrating that the drug was safe to take.
 
Indeed, researchers found encouragement beyond safety. Through analyzing brain scans, the team found that patients treated aducanumab had less amyloid plaques than those treated with the placebo.
 
"After one year, you can see no red on the image, meaning the amyloid has almost completely
disappeared," said Dr. Roger Nitsch, a co-author of the study and the director of the Institute for Regenerative Medicine at the University of Zurich.
 
In addition, there was a direct correlation between dose and effect – the higher the dose, the greater the clearance of the toxic protein clumps. Notably, however, the higher dosages were also associated with more side effects.
 
Though the purpose of the study was to establish safety, the team did carry out some memory tests with some promising results. "We believe that's a hint of efficacy," study co-author Dr. Alfred Sandrock, a neurologist and an executive vice president at Biogen,
 
"We're encouraged that, there appeared to be a slowing of cognitive decline at a dose-dependent manner, and also a dose-dependent slowing in functional decline," said study co-author Dr. Stephen Salloway.
 
The next phase of the study will definitively answer whether aducanumab holds cognitive benefits for Alzheimer’s patients. A total of 2,700 patients are slated to be enrolled in this next phase, which will be an international effort involving North America, Europe, and Asia.
 
 
Additional sources: BBC, Nature News
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
SEP 05, 2019
Clinical & Molecular DX
SEP 05, 2019
Muscular Dystrophy Drug by Sarepta Therapeutics: Approval or Rejection by Drug Regulating Authorities?
Duchenne Muscular Dystrophy (DMD is a rare, genetic disorder that hampers muscle movement and is the most common pediatric muscular dystrophy. I...
SEP 13, 2019
Clinical & Molecular DX
SEP 13, 2019
Apple Watch New Research App: A Boon to Women's Health
The Apple company, in 2018, enrolled more than 400,000 people in its Apple Heart Study conducted in partnership with Stanford University researchers....
SEP 22, 2019
Technology
SEP 22, 2019
Blood Incubation Using Laser Technology
The world’s first ever blood incubator was developed using laser technology and could someday prevent fatal blood transfusions in critically ill pati...
NOV 06, 2019
Clinical & Molecular DX
NOV 06, 2019
Opioid Addiction Can be Controlled Using an In-Brain Chip Technology: First U.S. Clinical Trial
Opioid addiction is a long-lasting (chronic) disease that can cause major health, social, and economic problems. Opioids are a class of drugs that act...
NOV 27, 2019
Health & Medicine
NOV 27, 2019
3D-printed cell traps catch cancer cells on the move
The early stages of metastasis, or the spread of cancer cells from the primary tumor site, are incredibly difficult to detect by analyzing blood samples. F...
DEC 22, 2019
Clinical & Molecular DX
DEC 22, 2019
Can Google Health's AI interpret X-rays as well as radiologists?
Patients presenting with severe coughs, chest pain or suspected infections are more than likely to be sent for a chest X-ray -- the most commonly taken med...
Loading Comments...